STOCK TITAN
  1. Home
  2. News
  3. FENC

Fennec Pharmaceuticals Inc - FENC STOCK NEWS

Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.

Fennec Pharmaceuticals Inc (FENC) delivers innovative therapies targeting cisplatin-induced hearing loss in pediatric cancer patients. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic partnerships.

Access timely reports on PEDMARK® development progress, including FDA communications and international commercialization efforts through European licensing agreements. Our curated news collection ensures you stay informed about pivotal Phase III trial outcomes and market expansion initiatives without promotional bias.

Key updates include earnings announcements, research publications, manufacturing developments, and conference participation details. All content undergoes rigorous verification to maintain compliance with financial disclosure standards and medical reporting best practices.

Bookmark this page for streamlined tracking of Fennec's progress in bringing ototoxicity prevention solutions to global markets. For real-time alerts on breaking news, subscribe to Stock Titan's regulatory update notifications.

News

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Rhea-AI Summary
Fennec Pharmaceuticals Inc. and Norgine enter an exclusive licensing agreement for PEDMARQSI®, the first approved therapy in EU and UK for reducing cisplatin-induced hearing loss in pediatric patients. Fennec to receive €40M upfront, up to €210M in milestones, and royalties. PEDMARQSI holds significant market potential with approvals in EU and UK based on Phase 3 trial data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.37%
Tags
none
-
News

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Rhea-AI Summary
FENC anticipates net revenues of $9.2 to $9.7 million for the fourth quarter of 2023, with full-year results to be disclosed soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
earnings
-
News

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Rhea-AI Summary
Fennec Pharmaceuticals Inc. announced that the U.S. FDA issued a public reminder to healthcare providers about the non-substitutability of PEDMARK with other sodium thiosulfate products. The FDA highlighted potential health risks associated with such substitutions, emphasizing the unique characteristics of PEDMARK. This communication aims to protect pediatric patients with localized, non-metastatic solid tumors from ototoxicity linked to cisplatin treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Fennec Announces Incremental $5 Million Investment from Petrichor

Rhea-AI Summary
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) announced the third closing of $5 million senior secured promissory notes under the existing agreement with Petrichor, amending it to provide access to up to $15 million of additional financing through December 31, 2024. The investment supports global PEDMARK® rollout, market expansion into the Adolescent and Young Adult (AYA) Patient Population, and strategic discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX) announces participation in upcoming conferences and one-on-one investor meetings. The company will be presenting at the Jefferies London Healthcare Conference and hosting investor meetings at the Craig Hallum Alpha Select Conference on November 16, 2023. The company's flagship product, PEDMARK®, is the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
conferences
-
News

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Fennec Pharmaceuticals Inc. reported net product revenue of $6.5 million in the third quarter, a 96% increase compared to the second quarter. The company's PEDMARK® drug addresses a significant unmet medical need in the pediatric oncology community. They also received approval for PEDMARQSI in the U.K. and are preparing for its launch in Europe. Cash and cash equivalents were $12.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.36%
Tags
earnings
News

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Rhea-AI Summary
Fennec Pharmaceuticals Inc. will release its Q3 2023 financial results on November 6, 2023. The company is hosting a conference call and webcast to discuss the results. The conference call details can be accessed through the provided link, and the webcast will be available on the company's website. A webcast replay will be archived for thirty days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences earnings
-
News

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Fennec Pharmaceuticals to participate in upcoming conferences and host investor meetings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences
-
News

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX) reported a 98% increase in net revenue in the second quarter of 2023, driven by growing physician awareness and usage of PEDMARK®. The company also appointed Adrian Haigh as Chief Operating Officer and expanded its leadership team. Financial results for Q2 2023 include $3.3 million in net product sales, a decrease in research and development expenses, and a net loss of $5.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
earnings
News

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Rhea-AI Summary
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) will release its second quarter 2023 financial results on August 3, 2023, before the U.S. financial markets open. The management will host a conference call and webcast on the same day to discuss the financial and business results. To access the call and webcast, registration is required using the provided link. The webcast replay will be available on the company's website for thirty days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.66%
Tags
conferences earnings
Stock FENC logo
Fennec Pharmaceuticals Inc

Nasdaq:FENC

FENC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

FENC Stock Data

140.73M
23.13M
16.2%
58.62%
7.02%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RESEARCH TRIANGLE PARK